Skip to main content

Table 1 Patient characteristics and pharmacokinetic values

From: Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: case report

Patient 1 2a 2b
Post-Injury Day 18 15 21
Treatment Day 15 4 11
Age (years) 30 28 28
Weight (kg) 78.8 77.1 60.1
Antifungal L-AmB L-AmB Voriconazole Voriconazole
Dose (mg) 400 400 320 320
Dose (mg/kg) 5.1 (24 h) 5.2 (24 h) 4.2 (12 h) 5.3 (12 h)
Peak (μg/mL) 25.5 58.4 10.4 3.5
Trough (μg/mL) 6.1 12.8 3.0 0.7
AUCτ(μg · h/mL) 262.5 534.7 67.5 24.1
T1/2 (h) 23.3 16.3 7.6 3.2
Vd (L/kg) 0.52 0.21 0.58 1.28
Clearance (mL/kg/min) 0.32 0.16 1.02 3.69
Plasma % bound 100% 100% 32.7 ± 8.2 22.1 ± 4.1%
Effluent % bound    55.6% (RUE) N/A
100% 100% 75.0% (abd.)
(all sites) (all sites) 90.5% (calc.)
eGFR (mL/min/1.73 m2) 19.9 75.8 126.1
AST/ALT (IU/L) 193/59 211/318 61/72
INR 1.4 1.4 1.2
  1. Dose interval: 24 hours for L-AmB, 12 hours for voriconazole. Abd, abdomen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; calc, calcaneus; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; RUE, right upper extremity; T1/2, half-life; Vd, volume of distribution.